Health Care [ 7/12 ] | Biotechnology [ 39/74 ]
NASDAQ | Common Stock
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis.
Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive.
The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers.
The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.
Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 11, 25 | 1.43 Increased by +34.91% | 1.55 Decreased by -8.01% |
| Oct 29, 24 | 1.07 Decreased by -2.73% | 1.07 |
| Jul 30, 24 | -1.82 Decreased by -283.84% | -1.55 Decreased by -17.42% |
| Apr 30, 24 | 0.64 Increased by +72.97% | 0.84 Decreased by -23.81% |
| Feb 13, 24 | 1.06 Increased by +70.97% | 1.16 Decreased by -8.62% |
| Oct 31, 23 | 1.10 Increased by +83.33% | 1.02 Increased by +7.84% |
| Aug 1, 23 | 0.99 Decreased by -1.98% | 0.83 Increased by +19.28% |
| May 2, 23 | 0.37 Decreased by -32.73% | 0.76 Decreased by -51.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 1.18 B Increased by +16.32% | 201.21 M Increased by +0.07% | Increased by +17.07% Decreased by -13.97% |
| Sep 30, 24 | 1.14 B Increased by +23.81% | 106.46 M Decreased by -37.84% | Increased by +9.36% Decreased by -49.80% |
| Jun 30, 24 | 1.04 B Increased by +9.34% | -444.60 M Decreased by -318.43% | Decreased by -42.60% Decreased by -299.77% |
| Mar 31, 24 | 880.89 M Increased by +8.93% | 169.55 M Increased by +681.22% | Increased by +19.25% Increased by +617.17% |
| Dec 31, 23 | 1.01 B Increased by +9.35% | 201.08 M Increased by +606.51% | Increased by +19.84% Increased by +546.10% |
| Sep 30, 23 | 919.02 M Increased by +11.63% | 171.27 M Increased by +51.87% | Increased by +18.64% Increased by +36.05% |
| Jun 30, 23 | 954.61 M Increased by +4.74% | 203.55 M Increased by +26.09% | Increased by +21.32% Increased by +20.38% |
| Mar 31, 23 | 808.67 M Increased by +10.29% | 21.70 M Decreased by -42.87% | Increased by +2.68% Decreased by -48.20% |